Natco Pharma gains 9% as firm launches generic version of Revlimid in US

In the past three months, Natco Pharma has outperformed the market by gaining 8 per cent, as compared to 8 per cent decline in the S&P BSE Sensex.

Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launching these strengths of lenalidomide.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.

At